7EJR
Crystal structure of V30M mutated transthyretin in complex with 8-chloro-9-oxo-9H-xanthene-3-carboxylic acid
Summary for 7EJR
| Entry DOI | 10.2210/pdb7ejr/pdb |
| Descriptor | Transthyretin, CALCIUM ION, 8-chloranyl-9-oxidanylidene-xanthene-3-carboxylic acid, ... (4 entities in total) |
| Functional Keywords | amyloidosis, inhibitor, complex, transport protein |
| Biological source | Homo sapiens (Human) |
| Total number of polymer chains | 2 |
| Total formula weight | 35056.41 |
| Authors | Kitakami, R.,Yokoyama, T.,Mizuguchi, M. (deposition date: 2021-04-02, release date: 2021-10-13, Last modification date: 2023-11-29) |
| Primary citation | Kitakami, R.,Inui, K.,Nakagawa, Y.,Sawai, Y.,Katayama, W.,Yokoyama, T.,Okada, T.,Kanamitsu, K.,Nakagawa, S.,Toyooka, N.,Mizuguchi, M. Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis. Bioorg.Med.Chem., 44:116292-116292, 2021 Cited by PubMed Abstract: Transthyretin is a tetrameric protein which functions as a transporter of thyroxine and retinol-binding protein. Misfolding and amyloid aggregation of transthyretin are known to cause wild-type and hereditary transthyretin amyloidosis. Stabilization of the transthyretin tetramer by low molecular weight compounds is an efficacious strategy to inhibit the aggregation pathway in the amyloidosis. Here, we investigated the inhibitory activities of anthraquinone and xanthone derivatives against amyloid aggregation, and found that xanthone-2-carboxylic acid with one chlorine or methyl group has strong inhibitory activity comparable with that of diflunisal, which is one of the best known stabilizers of transthyretin. X-ray crystallographic structures of transthyretin in complex with the compounds revealed that the introduction of chlorine, which is buried in a hydrophobic region, is important for the strong inhibitory effect of the stabilizer against amyloidogenesis. An in vitro absorption, distribution, metabolism and elimination (ADME) study and in vivo pharmacokinetic study demonstrated that the compounds have drug-like features, suggesting that they have potential as therapeutic agents to stabilize transthyretin. PubMed: 34225167DOI: 10.1016/j.bmc.2021.116292 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.451 Å) |
Structure validation
Download full validation report
